NCT04989725 (SUPPRESS) is a Phase 2 clinical trial of Standard arm in Head and Neck Cancer, sponsored by Centre hospitalier de l'Université de Montréal (CHUM).

Who is sponsoring NCT04989725?

NCT04989725 is sponsored by Centre hospitalier de l'Université de Montréal (CHUM).

What drugs are being tested in NCT04989725?

Interventions in NCT04989725: Standard arm, Experimental arm.

What condition does NCT04989725 study?

NCT04989725 studies Head and Neck Cancer, Metastatic Cancer, Oligoprogressive.

Is NCT04989725 still recruiting?

NCT04989725 is currently recruiting now. Last updated 12 December 2023.

Last reviewed 2023-12-12 · How we verify

NCT04989725: SUPPRESS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Stereotactic Ablative Radiotherapy for Oligo-Progressive Disease REfractory to Systemic Therapy in Metastatic Cancer

Recruiting now Phase 2 Last updated 12 December 2023

What this trial tests

Phase 2 trial testing Standard arm in Head and Neck Cancer in 46 participants. Currently enrolling.

Timeline

1 October 2021

Primary endpoint
1 December 2025

1 December 2027

Quick facts

Lead sponsor	Centre hospitalier de l'Université de Montréal (CHUM)
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	46
Start date	1 October 2021
Primary completion	1 December 2025
Estimated completion	1 December 2027
Sites	1 location across Canada

Drugs / interventions tested

Standard arm
Experimental arm

Conditions studied

Head and Neck Cancer — all drugs for Head and Neck Cancer →
Metastatic Cancer — all drugs for Metastatic Cancer →
Oligoprogressive — all drugs for Oligoprogressive →

Sponsor

Centre hospitalier de l'Université de Montréal (CHUM)

Who can join

18 and older, any sex, with Head and Neck Cancer or Metastatic Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A registry-based randomized phase II trial. A total of 46 patients with metastatic head and neck cancer on systemic therapy with oligoprogression to 1-5 extracranial lesions will be randomized using a 1:1 ratio to standard of care (begin next-line systemic therapy, best supportive care, continue current systemic line, based on treating physician decision) vs. receive stereotactic ablative radiotherapy to all oligoprogressive lesions while continuing their current systemic therapy.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Oligometastatic Head and Neck Cancer: Challenges and Perspectives.
Bahig H, Huang SH, O'Sullivan B. · · 2022 · cited 19× · PMID 36010888 · DOI 10.3390/cancers14163894
A novel prognostic score (HAMP) for head and neck cancer patients with single and multiple SBRT-treated lung metastases derived from retrospective analyses of survival outcome.
Vorbach SM, Seppi T, Sarcletti MP, Kollotzek S, et al · · 2025 · cited 1× · PMID 39114975 · DOI 10.1002/hed.27913

Verify or expand the search:

Other trials of Standard arm

Trials testing the same drug.

NCT04046705 — Comparison of Allogeneic Matched Related Haematopoietic Stem Cell Transplantation After a Reduced Intensity Conditioning · Phase 3 · unknown
NCT03148600 — Rehabilitation After Ileo-anal Pouch Surgery · NA · completed

Other recruiting trials for Head and Neck Cancer

Currently open trials in the same condition.

NCT07318220 — Prehabilitation Protocol for Head and Neck Cancer Patients · NA · recruiting
NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
NCT07467083 — Development and Application of a Nurse-Led Preemptive Symptom Management Protocol for Head and Neck Cancer Patients Unde · Phase 3 · recruiting
NCT07209189 — Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-esca · Phase 2 · recruiting
NCT06837480 — Photobiomodulation in Head and Neck Cancer-Related Chronic Lymphedema · NA · recruiting

Other Centre hospitalier de l'Université de Montréal (CHUM) trials

Trials by the same sponsor.

NCT06735638 — Outside the Cage (OTC) Robotic Esophagectomy · Phase 1 · not yet recruiting
NCT07533253 — Rescue Distal Thrombectomy in Treatment for Persistent Distal Occlusions · NA · not yet recruiting
NCT05225272 — Effectiveness of an Enhanced Recovery After Surgery Protocol in Patients Undergoing On-pump Cardiac Surgery · not yet recruiting
NCT07497061 — Comparison of Two Surgical Techniques for the Treatment of Trigger Fingers: Longitudinal Opening Versus Complete A1 Pull · NA · not yet recruiting
NCT07196410 — KAN-004 for Immune-Related Diarrhea or Colitis · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04989725 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Centre hospitalier de l'Université de Montréal (CHUM)
Last refreshed: 12 December 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04989725.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing